A296
/ Sichuan Kelun Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
August 18, 2025
Non-DC asset advancements are diversifying the innovation pipeline
(PRNewswire)
- "A296 (STING agonist): A Phase 1 trial is being carried out in China."
Trial status • Solid Tumor
December 09, 2024
A Study of Intratumoral KL340399 in Patients with Advanced Solid Tumors
(clinicaltrials.gov)
- P1 | N=30 | Recruiting | Sponsor: Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. | Trial completion date: Aug 2024 ➔ Jun 2025 | Trial primary completion date: Aug 2024 ➔ Jun 2025
Metastases • Trial completion date • Trial primary completion date • Oncology • Solid Tumor
June 27, 2024
A Study of KL340399 in Patients With Advanced Solid Tumors
(clinicaltrials.gov)
- P1 | N=30 | Recruiting | Sponsor: Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. | Not yet recruiting ➔ Recruiting | Trial completion date: May 2024 ➔ May 2025 | Trial primary completion date: May 2024 ➔ May 2025
Enrollment open • Metastases • Trial completion date • Trial primary completion date • Oncology • Solid Tumor
September 22, 2022
A Study of Intratumoral KL340399 in Patients With Advanced Solid Tumors
(clinicaltrials.gov)
- P1 | N=30 | Recruiting | Sponsor: Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
New P1 trial • Oncology • Solid Tumor
May 24, 2022
A Study of KL340399 in Patients With Advanced Solid Tumors
(clinicaltrials.gov)
- P1 | N=30 | Not yet recruiting | Sponsor: Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
New P1 trial • Oncology • Solid Tumor
1 to 5
Of
5
Go to page
1